Trials / Active Not Recruiting
Active Not RecruitingNCT06880549
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
A Phase 1, Open-label, Multicenter, Dose-escalation Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (estimated)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI) therapy in participants with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | mRNA-4106 | Intramuscular Injection |
| BIOLOGICAL | Nivolumab/Relatlimab | Intravenous infusion |
Timeline
- Start date
- 2025-03-25
- Primary completion
- 2029-01-10
- Completion
- 2029-01-10
- First posted
- 2025-03-17
- Last updated
- 2026-02-05
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06880549. Inclusion in this directory is not an endorsement.